Calliditas Therapeutics bags TARPEYO FDA approval for IgAN
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) has announced a landmark FDA approval for TARPEYO (budesonide) delayed release capsules, aimed at reducing kidney function ... Read More
Calliditas Therapeutics initiates Phase 3 NEFIGARD trial for Nefecon to treat IgA nephropathy
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate, Nefecon, for treating IgA nephropathy (IgAN), commonly ... Read More